
Spect
Spect is a YC Summer 2017 (S17) company. Based in Palo Alto, CA, USA; Remote. Team of 7.
About Spect
Summary
Spect builds an AI-powered retinal screening platform that brings vision disease detection into primary care settings. It targets the hundreds of millions of diabetic patients at risk for conditions such as diabetic retinopathy and glaucoma, who currently depend on ophthalmologists to manually read fundus images. Spect replaces that specialist-dependent, clinic-heavy workflow with automated diagnosis, cutting the cost and bottleneck out of preventive eye care.
Go-to-market
Primary care providers and community health settings are the point of entry, allowing screening to happen where diabetic patients already receive routine care rather than requiring referrals to eye clinics.
From the Y Combinator listing
Value-based retinal screening in primary care to prevent blindness.
Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.
Facts
- Healthcare / Healthcare -> Consumer Health and Wellness
- Palo Alto, CA, USA; Remote
- 7
- Inactive
- Early
Founders (3)
- Rishab Gargeya
- Ted Leng
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works